Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan PK Study: Food and Age Effects
NCT04551599Phase 1Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- Feb 2020
- Primary completion
- Feb 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (3 arms), sponsored by Alexion Pharmaceuticals. Primary endpoints: Area Under The Concentration Versus Time Curve From Time 0 To The Last Measurable Concentration, Area Under The Concentration Versus Time Curve From Time 0 Extrapolated To Infinity and 2 more. Started Feb 2020; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT04551599.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04551599.